Skip to main content
Signal8
Launch Terminal

Nanobiotix S.A. (NBTX)

Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Nanobiotix S.A. logo

Nanobiotix S.A.

NASDAQ:NBTXHealthcare
-7.19%$31.37
AH$31.37+0.00%vs close
Mkt Cap$1.6B
Float47.78M
O/S50.95M
Vol
$ Vol
RVOL
Inst Own11.4%
Earnings
Dilution
Nanobiotix S.A. logoNASDAQ:NBTX$31.37-7.19%
Phase Distribution
6 lead-sponsored trials·1 active·2 completed
Phase 12
Phase 1/22
Phase 2/31
Not applicable1
(1 more as collaborator)
Status Overview
Active, not recruiting1
Completed2
Stopped2
Unknown1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 2/3
    Completed

    NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall

    NBTXR3, Radiation therapy

    Adult Soft Tissue Sarcoma

    Enrollment
    180
    Start
    Mar 2015
    Primary Completion
    May 2018
    Completion
    Sep 2020
    NCT02379845
  • Phase 1/2
    Terminated

    NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers

    NBTXR3, IL or IA injection + SBRT

    Liver Cancer

    Enrollment
    23
    Start
    Jan 2016
    Primary Completion
    May 2020
    Completion
    May 2020
    NCT02721056
  • Phase 1/2
    Terminated

    NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma

    NBTXR3 activated by IMRT only, NBTXR3 activated by Brachytherapy & IMRT

    Prostate Cancer

    Enrollment
    5
    Start
    Nov 2017
    Primary Completion
    Mar 2020
    Completion
    Mar 2020
    NCT02805894
  • Phase 1
    Completed

    NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma of the Extremity

    NBTXR3

    Adult Soft Tissue Sarcoma

    Enrollment
    22
    Start
    Oct 2011
    Primary Completion
    May 2014
    Completion
    Feb 2015
    NCT01433068
  • Phase 1
    Active, not recruiting

    NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

    NBTXR3, Nivolumab

    Radiotherapy, Immunotherapy +9

    Enrollment
    145
    Start
    Jan 2019
    Primary Completion
    Apr 2027est.
    Completion
    Aug 2027est.
    NCT03589339
  • Not applicable
    Unknown status

    NBTXR3 and Radiation Therapy in Treating Patients With Locally Advanced SCC of the Oral Cavity or Oropharynx

    NBTXR3 activated by IMRT

    Head and Neck Cancer

    Enrollment
    75
    Start
    Jan 2014
    Primary Completion
    Feb 2023est.
    Completion
    Feb 2023est.
    NCT01946867
Search ClinicalTrials.gov for “Nanobiotix”